Replimune Group, Inc. (NASDAQ:REPL) Receives $19.43 Average Price Target from Brokerages

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) has been assigned a consensus rating of "Buy" from the nine ratings firms that are currently covering the stock, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $19.75.

Several research analysts recently issued reports on REPL shares. HC Wainwright lifted their target price on Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. lifted their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Finally, Piper Sandler upped their target price on shares of Replimune Group from $14.00 to $22.00 and gave the stock an "overweight" rating in a research note on Monday.

Replimune Group Stock Up 0.6%

Replimune Group stock traded up $0.06 during midday trading on Friday, reaching $9.69. The stock had a trading volume of 1,033,156 shares, compared to its average volume of 947,504. Replimune Group has a 12 month low of $4.93 and a 12 month high of $17.00. The company has a market capitalization of $746.97 million, a P/E ratio of -3.16 and a beta of 0.68. The company has a fifty day moving average price of $8.34 and a two-hundred day moving average price of $11.05. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter in the previous year, the business earned ($0.25) earnings per share. As a group, equities analysts expect that Replimune Group will post -2.97 EPS for the current fiscal year.

Insider Transactions at Replimune Group

In other news, CAO Andrew Schwendenman sold 3,287 shares of the company's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total value of $26,460.35. Following the transaction, the chief accounting officer now owns 68,284 shares of the company's stock, valued at approximately $549,686.20. This represents a 4.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Konstantinos Xynos sold 7,952 shares of the company's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $64,093.12. Following the completion of the transaction, the insider now directly owns 146,933 shares in the company, valued at approximately $1,184,279.98. The trade was a 5.13% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 74,907 shares of company stock worth $603,655. 8.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Replimune Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC boosted its position in shares of Replimune Group by 14.7% during the 4th quarter. SG Americas Securities LLC now owns 26,291 shares of the company's stock valued at $318,000 after acquiring an additional 3,374 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Replimune Group by 24.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company's stock valued at $198,000 after purchasing an additional 3,177 shares in the last quarter. Rhumbline Advisers lifted its position in Replimune Group by 8.3% during the fourth quarter. Rhumbline Advisers now owns 95,465 shares of the company's stock valued at $1,156,000 after purchasing an additional 7,317 shares during the last quarter. New York State Common Retirement Fund lifted its position in Replimune Group by 260.8% during the fourth quarter. New York State Common Retirement Fund now owns 43,204 shares of the company's stock valued at $523,000 after purchasing an additional 31,231 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Replimune Group by 7.3% in the 4th quarter. Bank of New York Mellon Corp now owns 174,518 shares of the company's stock worth $2,113,000 after buying an additional 11,893 shares in the last quarter. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.